Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis.

Michael P Pender,Sweera Rehan,Andrew Swayne,Alan Coulthard,Corey Smith,Kaye D Hooper,Leone Beagley,Rajiv Khanna,Zara A Ioannides,Scott R Burrows,Kerryn A Green,Peter A Csurhes,Pauline Crooks,Blake T Aftab,Nanette L Douglas,Michelle A Neller,Stefan Blum,Katherine H Thompson ,Tracey Hopkins ,Katherine Matthews

doi:10.1172/jci.insight.144624

Abstract

Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis.

Highlights

During the preparation of this manuscript, errors relating to data for BVMT-TL, BVMT-DR, PASAT3, and PASAT2 were inadvertently introduced into Figure 3C
Significant, or nearly significant, increases in attainment were observed at week 27 across two measures, the Controlled Oral Word Association Test (COWAT, a verbal fluency test) and the Paced Auditory Serial Addition Test (PASAT3, a working memory/processing speed task) (P = 0.074 and P = 0.0356 respectively, paired 2-tailed t test); after applying the Bonferroni correction for multiple comparisons, these P values no longer reached significance

Summary

Introduction

During the preparation of this manuscript, errors relating to data for BVMT-TL, BVMT-DR, PASAT3, and PASAT2 were inadvertently introduced into Figure 3C. Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis

Results

Conclusion